• Follow
  • Follow
  • Follow
  • Follow
U

Search



Shop

w

News

w

Blog

DONATE
Team Jack Foundation
  • About Us
    • Our Mission
    • Jack Hoffman
    • Board & Staff
    • Financials
  • Our Impact
    • Scientific Advisory Board
    • Sponsored Grants
    • Research Articles
  • Brain Cancer
    • What is Brain Cancer?
      • What is DIPG?
    • Brain Cancer Facts
    • Cancer Awareness Months
      • Brain Tumor Awareness Month
    • Family Resources
  • Events
  • Get Involved
    • Fundraise
      • Host an Event
      • Run For Team Jack
      • Birthday Fundraiser
    • Give
    • Our Sponsors
    • Volunteer
  • Heroes
  • Donate
  • Shop
  • Blog
  • News
Select Page

Get Involved

Clinical Trial Finder

Search Results

9-ING-41 in Patients with Advanced Cancers

Study Purpose

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patient - 1.
Is able to understand and voluntarily sign a written informed consent and is willing and able to comply with the protocol requirements including scheduled visits, treatment plan, laboratory tests and other study procedures. 2. Is aged ≥ 18 years. 3. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following: 1. Patient is intolerant of existing therapy(ies) known to provide clinical benefit for their condition. 2. Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit. 3. Malignancy has relapsed after standard therapy. 4. Malignancy for which there is no standard therapy that improves survival by at least 3 months. 4. Has evaluable tumor(s) by standard radiological and/or laboratory assessments as applicable to their malignancy
  • - in Part 3, patients with solid tumors must have least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) v1.1 criteria, measured preferably by computed tomography (CT) scan or magnetic resonance image (MRI).
In the case of patients with glioblastoma multiforme (GBM) or other central nervous system (CNS) tumors, the tumor must be measurable, defined as a clearly enhancing tumor with at two perpendicular diameters at entry equal or superior to 1cm. 5. Has laboratory function within specified parameters (may be repeated): 1. Adequate bone marrow function: absolute neutrophil count (ANC) ≥ 500/mL; hemoglobin ≥ 8.5 g/dL, platelets ≥ 50,000/mL. 2. Adequate liver function: transaminases (aspartate aminotransferase/ alanine aminotransferase, AST/ALT) and alkaline phosphatase ≤ 3 (≤ 5 X the upper limit of normal (ULN) in the setting of liver metastasis or infiltration with malignant cells) x ULN; bilirubin ≤ 1.5 x ULN. 3. Adequate renal function: creatinine clearance ≥ 60 mL/min (Cockcroft and Gault) 4. Adequate blood coagulation: international normalized ratio (INR) ≤ 2.3. 5. Serum amylase and lipase ≤ 1.5 x ULN. 6. Has adequate performance status (PS): Eastern Co-operative Oncology Group (ECOG) PS 0-2. 7. Has received the final dose of any of the following treatments/ procedures with the specified minimum intervals before first dose of study drug (unless in the opinion of the investigator and the study medical coordinator the treatments/ procedures will not compromise patient safety or interfere with study conduct and with IDMC agreement):
  • - Chemotherapy, immunotherapy, or systemic radiation therapy - 14 days or ≥ 5 half-lives (whichever is shorter) - Focal radiation therapy - 7 days.
  • - Systemic and topical corticosteroids - 7 days.
  • - Surgery with general anesthesia - 7 days.
  • - Surgery with local anesthesia - 3 days.
8. May continue endocrine therapies (e.g. for breast or prostate cancer) and/or anti-human epidermal growth factor (Her2) therapies while on this study. 9. Women of childbearing potential must have a negative baseline blood or urine pregnancy test within 72 hours of first study therapy. Women may be neither breastfeeding nor intending to become pregnant during study participation and must agree to use effective contraceptive methods (hormonal or barrier method of birth control, or true abstinence) for the duration of study participation and in the following 90 days after discontinuation of study treatment. 10. Male patients with partners of childbearing potential must take appropriate precautions to avoid fathering a child from screening until 90 days after discontinuation of study treatment and use appropriate barrier contraception or true abstinence. 11. Must not be receiving any other investigational medicinal product.

Exclusion Criteria:

  • - Patient - 1.
Is pregnant or lactating. 2. Is known to be hypersensitive to any of the components of 9-ING-41 or to the excipients used in its formulation. 3. Has not recovered from clinically significant toxicities as a result of prior anticancer therapy, except alopecia and infertility. Recovery is defined as ≤ Grade 2 CTCAE Version 4.03. 4. Has significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, or stroke within 6 months of the first dose of 9-ING-41, or cardiac arrhythmia requiring medical treatment detected at screening. 5. Has had a myocardial infarction within 12 weeks of the first dose of 9-ING-41 or has electrocardiogram (ECG) abnormalities that are deemed medically relevant by the investigator or study medical coordinator. 6. Has known symptomatic rapidly progressive brain metastases or leptomeningeal involvement as assessed by CT scan or MRI. Patients with stable asymptomatic brain metastases or leptomeningeal disease or slowly progressive disease are eligible provided that they have not required new treatments for this disease in a 28-day period before the first dose of study drug, and anticonvulsants and steroids are at a stable dose for a period of 14 days prior to the first dose of study drug. 7. Has had major surgery (not including placement of central lines) within 7 days prior to study entry or is planned to have major surgery during the course of the study (major surgery may be defined as any invasive operative procedure in which an extensive resection is performed, e.g. a body cavity is entered, organs are removed, or normal anatomy is altered. In general, if a mesenchymal barrier is opened (pleural cavity, peritoneum, meninges), the surgery is considered major) 8. Has any medical and/or social condition which, in the opinion of the investigator or study medical coordinator would preclude study participation. 9. Has received an investigational anti-cancer drug in the 14-day period before the first dose of study drug (or within 5 half-lives if longer) or is currently participating in another interventional clinical trial. 10. Has a current active malignancy other than the target cancer. 11. Is considered to be a member of a vulnerable population (for example, prisoners) Part 3 ARMB

Inclusion Criteria:

Patient
  • - 1.
Is able to understand and voluntarily sign a written informed consent and is willing and able to comply with the protocol requirements including scheduled visits, treatment plan, laboratory tests and other study procedures. 2. Is aged ≥ 18 years. 3. Has pathologically confirmed metastatic pancreatic cancer AND is previously untreated with systemic agents in the recurrence/metastatic setting. 4. Must have at least 1 measurable lesion per RECIST v1.1, measured preferably by computed tomography (CT) scan or magnetic resonance image (MRI) 5. Has laboratory function within specified parameters (may be repeated): e. Adequate bone marrow function: absolute neutrophil count (ANC) ≥ 500/mL; hemoglobin ≥ 8.5 g/dL, platelets ≥ 75,000/mL f. Adequate liver function: transaminases (aspartate aminotransferase/ alanine aminotransferase, AST/ALT) and alkaline phosphatase ≤ 3 (≤ 10 X the upper limit of normal (ULN) in the setting of liver metastasis or infiltration with malignant cells) x ULN; bilirubin ≤ 1.5 x ULN Adequate renal function: creatinine clearance ≥ 30 mL/min (Cockcroft and Gault) 6. Has Eastern Co-operative Oncology Group (ECOG) PS 0 or 1. 7. Has received the final dose of any of the following treatments/ procedures with the specified minimum intervals before first dose of study drug:
  • - Focal radiation therapy - 7 days.
  • - Surgery with general anesthesia - 7 days.
  • - Surgery with local anesthesia - 3 days.
8. May have received treatment with fluorouracil or gemcitabine as a radiation sensitizer in the adjuvant setting if the treatment was received at least 6 months before study enrollment. 9. May have received neoadjuvant chemotherapy with FOLFIRINOX if last dose given at least 6 months before study enrollment. 10. May have received prior cytotoxic doses of systemic chemotherapy in the adjuvant setting if last dose given at least 6 months before study enrollment. 11. Women of childbearing potential must have a negative baseline blood or urine pregnancy test within 72 hours of first study therapy. Women may be neither breastfeeding nor intending to become pregnant during study participation and must agree to use effective contraceptive methods (hormonal or barrier method of birth control, or true abstinence) for the duration of study participation and in the following 90 days after discontinuation of study treatment. 12. Male patients with partners of childbearing potential must take appropriate precautions to avoid fathering a child from screening until 90 days after discontinuation of study treatment and use appropriate barrier contraception or true abstinence. 13. Must not be receiving any other investigational medicinal product.Patient who meets ANY of the following criteria is not eligible for this Part 3 study Arm B:

Exclusion Criteria:

1. Is pregnant or lactating. 2. Is known to be hypersensitive to any of the components of 9-ING-41 or to the excipients used in its formulation. 3. Has endocrine or acinar pancreatic carcinoma. 4. Has not recovered from clinically significant toxicities as a result of prior anticancer therapy, except alopecia and/or infertility. Recovery is defined as ≤ Grade 2 severity per CTCAE, v5.0. 5. Has significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, or stroke within 6 months of the first dose of study therapy, or uncontrolled cardiac arrhythmia. 6. Has had a myocardial infarction within 12 weeks of the first dose of study therapy or has electrocardiogram (ECG) abnormalities that are deemed medically relevant by the investigator. 7. Has symptomatic rapidly progressive brain metastases or leptomeningeal involvement as assessed by CT scan or MRI. Patients with stable brain metastases or leptomeningeal disease or slowly progressive disease are eligible provided that they have not required new treatments for this disease in a 28-day period before the first dose of study drug, and anticonvulsants and steroids are at a stable dose for a period of 14 days prior to the first dose of study drug. 8. Has had major surgery (not including placement of central lines) within 7 days prior to study entry or is planned to have major surgery during the course of the study (major surgery may be defined as any invasive operative procedure in which an extensive resection is performed, e.g., a body cavity is entered, organs are removed, or normal anatomy is altered. In general, if a mesenchymal barrier is opened (pleural cavity, peritoneum, meninges), the surgery is considered major) 9. Has any medical and/or social condition which, in the opinion of the investigator or study medical coordinator would preclude study participation. 10. Has received an investigational anti-cancer drug in the 14-day period before the first dose of study drug (or within 5 half-lives if longer) or is currently participating in another interventional clinical trial. 11. Has a current active malignancy other than pancreatic cancer. 12. Is considered to be a member of a vulnerable population (for example, prisoners).

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03678883
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Actuate Therapeutics Inc.
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Active, not recruiting
Countries Belgium, Canada, France, Netherlands, Portugal, Spain, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
Additional Details

9-ING-41 is a first-in-class, intravenously administered, maleimide-based small molecule potent selective GSK-3β inhibitor with significant pre-clinical antitumor activity. GSK-3 is a serine/threonine kinase initially described as a key regulator of metabolism and has a role in diverse disease processes including cancer, immune disorders, pathologic fibrosis, metabolic disorders, and neurological disorders. GSK-3 has two ubiquitously expressed and highly conserved isoforms, GSK-3α and GSK-3β, with both shared and distinct substrates and functional effects. GSK-3β is particularly important in tumor progression and modulation of oncogenes (including beta-catenin, cyclin D1 and c-Myc), cell cycle regulators (e.g. p27Kip1) and mediators of epithelial-mesenchymal transition (e.g. zinc finger protein SNAI1, Snail). Aberrant overexpression of GSK-3β has been shown to promote tumor growth and chemotherapy resistance in various solid tumors including colon, ovarian, and pancreatic cancers and glioblastoma through differential effects on the pro-survival nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and c-Myc pathways as well on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and p53-mediated apoptotic mechanisms. GSK-3β helps maintain malignant cell survival and proliferation, particularly in terms of mediating resistance to standard anti-cancer therapies, through the NF-κB pathway. GSK-3β has been established as a potential anticancer target in human bladder, breast, colorectal, glioblastoma, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and thyroid cancers as well as chronic lymphocytic leukemia and lymphomas. 9-ING-41 is a small molecule potent selective GSK-3β inhibitor with broad spectrum pre-clinical antitumor activity. It's modes of action include downregulation of NF-κB and decreasing the expression NF-κB target genes including cyclin D1, Bcl-2, anti-apoptotic protein (XIAP) and B-cell lymphoma-extra large (Bcl-XL) leading to inhibition of tumor growth in multiple solid tumor cell and lymphoma lines and patient derived xenograft (PDX) models. NF-κB is constitutively active in cancer cells and promotes anti-apoptotic molecule expression. NF-κB activation is particularly important in cancer cells that have become chemo- and/or radio-resistant. 9-ING-41 also has significant activity in pre-clinical models of pathological pleural and pulmonary fibrosis. 9-ING-41 has significant in vitro and in vivo activity as a single agent and/or in combination with standard cytotoxic chemotherapies in a spectrum of solid tumors and hematological malignancies including bladder, breast, glioblastoma, neuroblastoma, pancreatic, sarcomas, and renal cancers as well as lymphomas. The 1801 had three parts:

  • - Completed: Part 1 (9-ING-41 as monotherapy): The standard 3+3 dose escalation design will be applied to all dose cohorts until the Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D) is identified.
  • - Completed: 9-ING-41 combined with standard anticancer agents: The 3+3 dose escalation study design will be used for 8 chemotherapy combination regimens (9-ING-41 plus gemcitabine, doxorubicin, lomustine, carboplatin, irinotecan, nab-paclitaxel plus gemcitabine, paclitaxel plus carboplatin, pemetrexed plus carboplatin) to identify the MTD/RP2D of each regimen.
  • - Part 3: A randomized Phase 2 study of 9-ING-41 either once or twice weekly with gemcitabine and nab-paclitaxel (GA) versus GA alone for patients with previously untreated metastatic or locally advanced pancreatic cancer is now open.

Arms & Interventions

Arms

Experimental: 9-ING-41

Drug: 9-ING-41

Experimental: 9-ING-41 plus Gemcitabine

Drugs: Gemcitabine - 21 day cycle. 9-ING-41

Experimental: 9-ING-41 plus Doxorubicin

Drugs: Doxorubicin. 9-ING-41

Experimental: 9-ING-41 plus Lomustine

Drugs: Lomustine. 9-ING-41.

Experimental: 9-ING-41 plus Carboplatin

Drugs: Carboplatin. 9-ING-41.

Experimental: 9-ING-41 plus nab paclitaxel Gemcitabine

Drugs: Nab-paclitaxel. Gemcitabine - 28 day cycle. 9-ING-41.

Experimental: 9-ING-41 plus Paclitaxel/Carboplatin

Drugs: Paclitaxel. Carboplatin. 9-ING-41.

Experimental: 9-ING-41 plus Irinotecan

Drugs: Irinotecan. 9-ING-41.

Interventions

Drug: - 9-ING-41

Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.

Drug: - Gemcitabine - 21 day cycle

Gemcitabine 1250 mg/m2 as a 30-minute intravenous infusion on Days 1 and 8 of a 21-day cycle

Drug: - Doxorubicin.

Doxorubicin 75 mg/m2, intravenous bolus on Day 1 of a 21-day cycle up to a maximum lifetime dose of 550 mg/m2.

Drug: - Lomustine

Lomustine 30 mg/m² orally as a single dose, weekly for twelve weeks.

Drug: - Carboplatin.

Carboplatin AUC 6 IV over 1 hour on Day 1 of a 21-day cycle.

Drug: - Nab paclitaxel.

Nab-paclitaxel 125 mg/m2 intravenously on Days 1, 8 and 15 of a 28-day cycle

Drug: - Paclitaxel.

Paclitaxel 175 mg/m2 intravenously over 3 hours on Day 1 of a 21-day cycle.

Drug: - Gemcitabine - 28 day cycle

Gemcitabine 1000 mg/m2 intravenously over 30-minutes on Days 1, 8 and 15 of a 28-day cycle

Drug: - Irinotecan

Irinotecan 350 mg/m2 intravenously over 90-minutes on Day 1 of a 21-day cycle

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Mayo Clinic, Phoenix 5308655, Arizona 5551752

Status

Address

Mayo Clinic

Phoenix 5308655, Arizona 5551752, 85054

Arizona Oncology Associates, Tucson 5318313, Arizona 5551752

Status

Address

Arizona Oncology Associates

Tucson 5318313, Arizona 5551752, 85704

The University of Arizona Cancer Center, Tucson 5318313, Arizona 5551752

Status

Address

The University of Arizona Cancer Center

Tucson 5318313, Arizona 5551752, 85719

University of California Irvine Health, Orange 5379513, California 5332921

Status

Address

University of California Irvine Health

Orange 5379513, California 5332921, 92868

San Francisco 5391959, California 5332921

Status

Address

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco 5391959, California 5332921, 94115

Christiana Care Health Services, Newark 4143861, Delaware 4142224

Status

Address

Christiana Care Health Services

Newark 4143861, Delaware 4142224, 19709

Sibley Memorial Hospital, Washington D.C. 4140963, District of Columbia 4138106

Status

Address

Sibley Memorial Hospital

Washington D.C. 4140963, District of Columbia 4138106, 20016

Florida Cancer Specialists - South, Fort Myers 4155995, Florida 4155751

Status

Address

Florida Cancer Specialists - South

Fort Myers 4155995, Florida 4155751, 33901

Miami Cancer Institute, Miami 4164138, Florida 4155751

Status

Address

Miami Cancer Institute

Miami 4164138, Florida 4155751, 33176

Florida Cancer Specialists - North, St. Petersburg 4171563, Florida 4155751

Status

Address

Florida Cancer Specialists - North

St. Petersburg 4171563, Florida 4155751, 33705

Chicago 4887398, Illinois 4896861

Status

Address

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Chicago 4887398, Illinois 4896861, 60611

Des Moines Oncology Research Association, Des Moines 4853828, Iowa 4862182

Status

Address

Des Moines Oncology Research Association

Des Moines 4853828, Iowa 4862182, 50309

Kansas University Cancer Center, Kansas City 4273837, Kansas 4273857

Status

Address

Kansas University Cancer Center

Kansas City 4273837, Kansas 4273857, 66160

Ochsner Clinic Foundation, New Orleans 4335045, Louisiana 4331987

Status

Address

Ochsner Clinic Foundation

New Orleans 4335045, Louisiana 4331987, 70121

University of Michigan, Ann Arbor 4984247, Michigan 5001836

Status

Address

University of Michigan

Ann Arbor 4984247, Michigan 5001836, 48109

Minneapolis 5037649, Minnesota 5037779

Status

Address

MetroMetro-Minnesota Community Oncology Research Consortium (MMCORC)

Minneapolis 5037649, Minnesota 5037779, 55416

Mayo Clinic, Rochester 5043473, Minnesota 5037779

Status

Address

Mayo Clinic

Rochester 5043473, Minnesota 5037779, 55905

Comprehensive Cancer Centers of Nevada, Las Vegas 5506956, Nevada 5509151

Status

Address

Comprehensive Cancer Centers of Nevada

Las Vegas 5506956, Nevada 5509151, 89128

Morristown Medical Center, Morristown 5101427, New Jersey 5101760

Status

Address

Morristown Medical Center

Morristown 5101427, New Jersey 5101760, 07960

Capital Health Medical Center/ Hopewell, Pennington 5102535, New Jersey 5101760

Status

Address

Capital Health Medical Center/ Hopewell

Pennington 5102535, New Jersey 5101760, 08534

MD Anderson Cancer Center at Cooper, Voorhees Township 5105860, New Jersey 5101760

Status

Address

MD Anderson Cancer Center at Cooper

Voorhees Township 5105860, New Jersey 5101760, 08043

New York 5128581, New York 5128638

Status

Address

Columbia University- Irving Medical Center

New York 5128581, New York 5128638, 10032

Stony Brook University Hospital, Stony Brook 5139865, New York 5128638

Status

Address

Stony Brook University Hospital

Stony Brook 5139865, New York 5128638, 11794

Duke University Medical Center, Durham 4464368, North Carolina 4482348

Status

Address

Duke University Medical Center

Durham 4464368, North Carolina 4482348, 27710

Oregon Health and Science University, Portland 5746545, Oregon 5744337

Status

Address

Oregon Health and Science University

Portland 5746545, Oregon 5744337, 97239

St. Luke's University Health Network, Bethlehem 5180225, Pennsylvania 6254927

Status

Address

St. Luke's University Health Network

Bethlehem 5180225, Pennsylvania 6254927, 18015

Allegheny Health Network, Pittsburgh 5206379, Pennsylvania 6254927

Status

Address

Allegheny Health Network

Pittsburgh 5206379, Pennsylvania 6254927, 15212

Rhode Island Hospital, Providence 5224151, Rhode Island 5224323

Status

Address

Rhode Island Hospital

Providence 5224151, Rhode Island 5224323, 02903

Prisma Health Cancer Institute, Greenville 4580543, South Carolina 4597040

Status

Address

Prisma Health Cancer Institute

Greenville 4580543, South Carolina 4597040, 26905

Sanford Research, Sioux Falls 5231851, South Dakota 5769223

Status

Address

Sanford Research

Sioux Falls 5231851, South Dakota 5769223, 57105

West Cancer Center, Germantown 4624601, Tennessee 4662168

Status

Address

West Cancer Center

Germantown 4624601, Tennessee 4662168, 38138

Baptist Clinical Research Institute, Memphis 4641239, Tennessee 4662168

Status

Address

Baptist Clinical Research Institute

Memphis 4641239, Tennessee 4662168, 38120

Nashville 4644585, Tennessee 4662168

Status

Address

Sarah Cannon Research Institute- Tennessee Oncology-Nashville

Nashville 4644585, Tennessee 4662168, 37203

Vanderbilt-Ingram Cancer Center, Nashville 4644585, Tennessee 4662168

Status

Address

Vanderbilt-Ingram Cancer Center

Nashville 4644585, Tennessee 4662168, 37232

Dallas 4684888, Texas 4736286

Status

Address

Texas Oncology- Charles A. Sammons Cancer Center

Dallas 4684888, Texas 4736286, 75246

UT Southwestern Medical Center, Dallas 4684888, Texas 4736286

Status

Address

UT Southwestern Medical Center

Dallas 4684888, Texas 4736286, 75390

Utah Cancer Specialists, Salt Lake City 5780993, Utah 5549030

Status

Address

Utah Cancer Specialists

Salt Lake City 5780993, Utah 5549030, 84124

Fred Hutchinson Cancer Research Center, Seattle 5809844, Washington 5815135

Status

Address

Fred Hutchinson Cancer Research Center

Seattle 5809844, Washington 5815135, 98109

West Virginia University, Morgantown 4815352, West Virginia 4826850

Status

Address

West Virginia University

Morgantown 4815352, West Virginia 4826850, 26506

UW Carbone Cancer Center, Madison 5261457, Wisconsin 5279468

Status

Address

UW Carbone Cancer Center

Madison 5261457, Wisconsin 5279468, 53792

International Sites

UZA- Antwerpen, Edegem 2799007, Antwerp, Belgium

Status

Address

UZA- Antwerpen

Edegem 2799007, Antwerp, 2650

Imelda VZW, Bonheiden 2801539, Belgium

Status

Address

Imelda VZW

Bonheiden 2801539, , 2820

UZ Gent, Ghent 2797656, Belgium

Status

Address

UZ Gent

Ghent 2797656, , 9000

UZ Leuven Gasthuisberg, Leuven 2792482, Belgium

Status

Address

UZ Leuven Gasthuisberg

Leuven 2792482, , 3000

Cross Cancer Institute, Edmonton 5946768, Alberta 5883102, Canada

Status

Address

Cross Cancer Institute

Edmonton 5946768, Alberta 5883102, T6G 1Z2

QE II Health Sciences Centre, Halifax 6324729, Nova Scotia 6091530, Canada

Status

Address

QE II Health Sciences Centre

Halifax 6324729, Nova Scotia 6091530, B3H 2Y9

Greenfield Park 5966078, Quebec 6115047, Canada

Status

Address

Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre

Greenfield Park 5966078, Quebec 6115047, G4V 2H1

Jewish General Hospital, Montreal 6077243, Quebec 6115047, Canada

Status

Address

Jewish General Hospital

Montreal 6077243, Quebec 6115047, H3T 1E2

McGill University Health Centre, Montreal 6077243, Quebec 6115047, Canada

Status

Address

McGill University Health Centre

Montreal 6077243, Quebec 6115047, H4A 3J1

Sherbrooke 6146143, Quebec 6115047, Canada

Status

Address

Centre Hospitalier Universitaire de Sherbrooke

Sherbrooke 6146143, Quebec 6115047, J1H 5N4

Besançon 3033123, Bourgogne-Franche-Comté 11071619, France

Status

Address

Center Hospitalier Regional Universitaire de Besancon - Site Jean Minjoz

Besançon 3033123, Bourgogne-Franche-Comté 11071619, 25030

CHRU Brest Hopital Morvan, Brest 3030300, Brittany Region 3030293, France

Status

Address

CHRU Brest Hopital Morvan

Brest 3030300, Brittany Region 3030293, 29200

Hopital Claude Huriez, Lille 2998324, Hauts-de-France 11071624, France

Status

Address

Hopital Claude Huriez

Lille 2998324, Hauts-de-France 11071624, 59037

Institute de Cancerologie de Lorraine, Vandœuvre-lès-Nancy 2970797, Meurthe-et-Moselle, France

Status

Address

Institute de Cancerologie de Lorraine

Vandœuvre-lès-Nancy 2970797, Meurthe-et-Moselle, 54500

Institut Bergonie, Bordeaux 3031582, Nouvelle-Aquitaine 11071620, France

Status

Address

Institut Bergonie

Bordeaux 3031582, Nouvelle-Aquitaine 11071620, 33076

Insitut de Cancerologie de l'Ouest, Saint-Herblain 2979590, Pays de la Loire Region 2988289, France

Status

Address

Insitut de Cancerologie de l'Ouest

Saint-Herblain 2979590, Pays de la Loire Region 2988289, 44800

Hopital de la Timone, Marseille 2995469, France

Status

Address

Hopital de la Timone

Marseille 2995469, , 13005

Netherlands Cancer Institute, Amsterdam 2759794, Netherlands

Status

Address

Netherlands Cancer Institute

Amsterdam 2759794, , 1066 CX

Fundacao Champalimaud, Lisbon 2267057, Portugal

Status

Address

Fundacao Champalimaud

Lisbon 2267057, , 1400-038

Hospital Da Luz, Lisbon 2267057, Portugal

Status

Address

Hospital Da Luz

Lisbon 2267057, , 1500-650

Centro Hospitalar Universitario Sao Joao, Porto 2735943, Portugal

Status

Address

Centro Hospitalar Universitario Sao Joao

Porto 2735943, , 4200-319

Vall d'Hebron Institute of Oncology, Barcelona 3128760, Spain

Status

Address

Vall d'Hebron Institute of Oncology

Barcelona 3128760, , 08035

Institut Catala d'Oncologia, Barcelona 3128760, Spain

Status

Address

Institut Catala d'Oncologia

Barcelona 3128760, , 8908

Hospital Clinico U San Carlos (HSC), Madrid 3117735, Spain

Status

Address

Hospital Clinico U San Carlos (HSC)

Madrid 3117735, , 28050

Madrid 3117735, Spain

Status

Address

START Madrid-HM CIOCC Hospital Universitario

Madrid 3117735, , 28050

INCLIVA University of Valencia, Valencia 2509954, Spain

Status

Address

INCLIVA University of Valencia

Valencia 2509954, , 46010

Resources

  • Patient and Caregiver Survey
  • Clinical Trial Endpoints
  • Research Resources
Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Make an impact through your inbox

News, upcoming events and research updates delivered straight to your inbox.

  • This field is for validation purposes and should be left unchanged.
MAKE AN IMPACT

Donate today to help the Team Jack Foundation fund research and fight pediatric brain cancer.

Make a Donation
  • About Us
  • Our Mission
  • Jack Hoffman
  • Board & Staff
  • Fund Allocation
  • Financials
  • Our Impact
  • Scientific Advisory Board
  • Sponsored Grants
  • Research Articles
  • Brain Cancer
  • Family Resources
  • Get Involved
  • Fundraise
  • Give
  • Events
  • Our Sponsors
  • Volunteer
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
seal of transparency badge - 2019 Gold
combined health agencies drive member charity badge
Share Omaha member badge
© 2021 Team Jack Foundation. PO Box 607, Atkinson, NE, 68713. All Rights Reserved. Team Jack Foundation, Inc. is exempt from federal income tax under section 501(c)3, ID Number 46-2301134, of the internal revenue code. All contributions to the Foundation are tax deductible. Privacy Policy • Contact